Navigation Links
Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
Date:4/25/2008

increased, leading to a decline in 3TC sales.

ZEFFIX - Chronic hepatitis B infection

Shire receives royalties from GSK on worldwide ZEFFIX sales. Royalties from sales of ZEFFIX for the three months to March 31, 2008 were $10.4 million, an increase of 14% compared to the same period in 2007 (2007: $9.1 million). The impact of foreign exchange movements has contributed 13% to the reported growth; excluding favourable foreign exchange movements there has been a marginal increase of 1% compared to the same period in 2007.

Other

Other royalties are primarily in respect of REMINYL and REMINYL XL (known as RAZADYNE and RAZADYNE ER in the US), a product marketed worldwide (excluding the UK and the Republic of Ireland) by Janssen Pharmaceutical N.V. ("Janssen"), an affiliate of Johnson & Johnson. Shire has the exclusive marketing rights in the UK and the Republic of Ireland.

Sales of the REMINYL/RAZADYNE range, for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer's type, continue to grow.

Litigation proceedings relating to 3TC, COMBIVIR, EPIVIR, EPZICOM, RAZADYNE, RAZADYNE ER, REMINYL, REMINYL XL and ZEFFIX are ongoing. Further information on these litigations can be found in our filings with the SEC, including our Annual Report on Form 10-K for the year to December 31, 2007.

4. Financial details

Cost of product sales

The cost of product sales increased by 38% to $90.3 million for the three months to March 31, 2008 (14% of product sales), up from $65.3 million in the corresponding period in 2007 (2007: 14% of product sales). The increase in cost of product sales is in line with the growth in product sales of 37%.

Research and development ("R&D")

R&D expenditure increased to $119.1 million for the three months to March 31, 2008 (19% of product sales), up from $79.0 million in the corresponding period in 2007 (2007: 17% of product sales). Contributing to the increased
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 The Mosaic Company (NYSE: MOS ... 2010 earnings results and financial tables on Tuesday, January ... New York Stock Exchange. Results will be available ... Company will host a conference call with presentation slides ... The call will begin at 11:00 a.m. Eastern ...
(Date:12/15/2009)... Thomson Reuters ... become the first drug pipeline database to fully ... This highly anticipated new content is being provided ... ,, Thomson Pharma will offer ... press releases, conferences, and other sources across all ...
(Date:12/14/2009)... 14 Vermillion, Inc. (Pink Sheets: ... William C. Wallen, Ph.D. Chief Scientific Officer, ... IDEXX Laboratories, will be joining its board ... plan. ,, "Bill brings more than ... diagnostics and biotechnology," said Gail Page, Vermillion ...
(Date:12/14/2009)... Dec. 14 Boston Scientific Corporation (NYSE: ... public offering of $2 billion aggregate principal amount of ... The public offering consists of $850 million of ... 6.00 percent notes due January 2020 and $300 million ... Scientific plans to use the net proceeds for general ...
Breaking Biology Technology:Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3
... 2, 2008 IDEXX,Laboratories, Inc. (Nasdaq: ... shipped,delivered and recognized first quarter revenue for ... next-generation point-of-care,analyzers: the Catalyst Dx(TM) for chemistry ... Catalyst Dx combines the convenience of,immediate results ...
... multiple ... - Launch scheduled for April 2008 in the United States and May ... ... Kingdom, April 2,/PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. and,Croda Health Care, the worldwide ...
... Buyer for Marketed Product Ganite(R), Lloyd Sanders Assumes Chief ... N.J., April 2, 2008 Genta,Incorporated (Nasdaq: GNTA ... its operations to conserve cash and focus on its,priority ... that its appeal of an adverse decision by the ...
Other Biology Technology:IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer 2The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies' Ingredients for New Essentially Brand 2The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies' Ingredients for New Essentially Brand 3The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies' Ingredients for New Essentially Brand 4The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies' Ingredients for New Essentially Brand 5Genta Restructures Operations to Focus on Priority Initiatives 2Genta Restructures Operations to Focus on Priority Initiatives 3Genta Restructures Operations to Focus on Priority Initiatives 4
(Date:12/14/2009)... from the Astrobiology Centre (INTA-CSIC) has shown that hydrogen ... formation of the most basic biological molecules can be ... carry out this study, published in the journal ... conditions of the early Earth. , "We have shown ... it produces hydrogen cyanide, a substance that could have ...
(Date:12/14/2009)... preventing some of the stresses of open surgery on the ... organ dysfunction. Laparoscopy is a type of surgery in the ... By adding another gas to the carbon dioxide used to ... Medical Center have found they can preserve more normal blood ... (ENO) helped to open blood vessels and keep blood flowing, ...
(Date:12/13/2009)... are associated with the health of the human lung. ... from 63 centres in Europe and Australia sheds new ... The new findings provide hope for better treatment for ... asthma. In the past it has been difficult to ... the health of the lung are not completely understood. ...
Breaking Biology News(10 mins):Prussian blue linked to the origin of life 2Gas improves blood flow and organ status during minimally invasive surgery 2New genes for lung disease discovered 2Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co Develop and Commercialize Compounds for Obesity 60478 1Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co Develop and Commercialize Compounds for Obesity 60478 2Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co Develop and Commercialize Compounds for Obesity 60478 3Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co Develop and Commercialize Compounds for Obesity 60478 4Duke develops nano scale drug delivery for chemotherapy 10597 1Duke develops nano scale drug delivery for chemotherapy 10597 2Study spotlights efficacy of questionnaire to identify patients at high risk for lung cancer 60475 1
... diphenyl ethers (PBDEs), chemicals used as fire retardants, can be ... television, computer, toaster and the sofa. Now, as reported ... are being found in alarming concentrations, in human blood and ... , In addition, these industrial chemicals have been ...
... teeth, neck injuries and abrasions in the mouth, also ... athletes. According to the U.S. Centers for Disease Control, ... room visits each year. , One may assume ... some 200,000 cases annually, mouthguards have been known to ...
... dioxide increasing in the atmosphere may affect the microbial life in ... source, warned Dr Ian Joint at a Science Media Centre press ... ocean bacteria to find out how they will respond to an ... sequenced 300 million bases of DNA, about one tenth the size ...
Other Biology News:Chemicals used as fire retardants could be harmful, UC-Riverside researchers say 2Chemicals used as fire retardants could be harmful, UC-Riverside researchers say 3Chemicals used as fire retardants could be harmful, UC-Riverside researchers say 4To keep mouths safe, don't just wear a mouthguard; keep it clean 2
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Amyloid stain....
...
Human sIL-2R/CD25 ELI-PAIR Kit...
Biology Products: